Aura Biosciences News

Raj Parekh to Exit Board at Aura Biosciences' Meeting

TipRanksApr 15 16:22 ET

Aura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial Health

TipRanksMar 29 03:07 ET

Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)

TipRanksMar 28 08:40 ET

Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)

TipRanksMar 28 06:40 ET

We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate

Yahoo FinanceMar 28 06:12 ET

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)

TipRanksMar 27 15:40 ET

Aura Biosciences Shares Rise Following Q4 Results

Aura Biosciences (AURA) shares were up more than 2% in recent Wednesday trading after the clinical-stage biotechnology company reported its Q4 results. Earlier, the company booked a Q4 net loss of $22

MT NewswiresMar 27 14:00 ET

Aura Biosciences GAAP EPS of -$1.93

Seeking AlphaMar 27 13:52 ET

Aura Biosciences: A Strong Buy on Clinical Progress and Financial Stability

TipRanksMar 27 13:05 ET

Recap: Aura Biosciences Q4 Earnings

Aura Biosciences (NASDAQ:AURA) reported its Q4 earnings results on Wednesday, March 27, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsAura Biosciences beat estimat

BenzingaMar 27 09:25 ET

Aura Biosciences Inc Files For Mixed Shelf Offering Of Up To $350M

Aura Biosciences Inc Files For Mixed Shelf Offering Of Up To $350M

BenzingaMar 27 08:18 ET

Express News | Aura Biosciences' Cash And Cash Equivalents And Marketable Securities Totaling $226.2M Is Expected To Provide Cash Runway Into 2H 2026

Moomoo 24/7Mar 27 07:15 ET

Express News | Aura Biosciences FY 2023 EPS $(1.93) Misses $(1.82) Estimate

Moomoo 24/7Mar 27 07:14 ET

Aura Biosciences Cash, Cash Equivalents as at Dec. 31 $226.2M>AURA

Aura Biosciences Cash, Cash Equivalents as at Dec. 31 $226.2M>AURA

Dow JonesMar 27 07:02 ET

Aura Biosciences Has a Strong Cash Position Into 2H 2026 >AURA

Aura Biosciences Has a Strong Cash Position Into 2H 2026 >AURA

Dow JonesMar 27 07:01 ET

Press Release: Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate L

Dow JonesMar 27 07:00 ET

11 Oversold Biotech Stocks To Buy Right Now

Yahoo FinanceMar 17 17:20 ET

Aura Biosciences Insider Ups Holding By 232% During Year

From what we can see, insiders were net buyers in Aura Biosciences, Inc.'s (NASDAQ:AURA ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. Altho

Simply Wall StMar 13 06:15 ET

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indica

BusinesswireFeb 26 07:00 ET

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersAura Biosciences (NASDAQ:AURA) stock moved upwards by 44.3% to $13.0 during Tuesday's pre-market session. The company's market cap stands at $640.3 million. Galera Therapeutics (NASDAQ:GRTX) sh

BenzingaJan 9 08:06 ET